P/B
18,2
Nutriband
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
$97.2M
Market Cap • 9/25/2026
2016
(10 years)
Founded
2017
(9 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
60,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
97,2M
EV
97,5M
EV/Revenue
60,3
EV/EBITDA
-14,1
EV/EBIT
-13,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-48,8M
Profitability
Gross Margin
33,1%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
75,1%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
9,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
3,1%
CAGR Op. Income 5Y
18,5%
CAGR Net Income 5Y
17,3%
CAGR EPS 5Y
4,7%
CAGR OCF 5Y
59,5%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,7
Quick Ratio
0,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!